Purdue continues OxyContin patent battle
10-10-2017
Savushkin / iStockphoto.com
The US Court of Appeals for the Federal Circuit has affirmed a decision by the Patent Trial and Appeal Board (PTAB) which found that two patent applications by Purdue Pharma were unpatentable.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
US Court of Appeals for the Federal Circuit, Purdue Pharma, patent, unpatentable, Recro Technology, PTAB,
